A 62-year-old male with colorectal cancer is in follow-up. Which medication should no longer be on his MAR?

In the context of a 62-year-old male with colorectal cancer undergoing follow-up, the medication that should no longer be on his medication administration record (MAR) is prednisone. This is because prednisone is a corticosteroid that can be used to reduce inflammation and symptoms associated with certain conditions, but it may also have significant side effects, particularly in the context of cancer treatment.

For patients undergoing treatment for cancer, particularly those who may be dealing with immune system challenges or potential interactions with chemotherapy, the management of medications becomes crucial. Corticosteroids like prednisone can suppress the immune system, increase blood sugar levels, and contribute to other complications that patients must avoid.

While gabapentin and ondansetron may still be relevant for managing neuropathic pain and nausea, respectively, the use of lactobacillus, a probiotic, can also be considered in some cancer patients to help with gut health. However, the potential for prednisone to cause complications makes it a candidate for discontinuation in this scenario. The physician may have assessed that the risks outweigh the benefits in this specific case, leading to its removal from the MAR.